Ranbaxy Laboratories launches Letrozole Tablets 2.5mg in UK, Romania and France

Ranbaxy Laboratories has launched Letrozole Tablets 2.5mg in UK, Romania and France. Letrozole is the bio equivalent of Femera, the innovator product of Novartis, that has the market size of $58 million in UK, $9 million in France and $5.5 million in Romania. Letrozole is an Antineoplastics , indicated for the treatment of breast cancer.

Ranbaxy’s subsidiary companies, Ranbaxy (UK), Terapia Ranbaxy and Ranbaxy Pharmacy Generiques will be marketing this product in UK, Romania and France.

Ranbaxy Laboratories, is India's largest pharmaceutical company. The company has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.